Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20084226 | 0.88 | SKP2 (0.46) | TDP1CYP3A4ACHETAAR1PTPN1 | |
| SCHEMBL10510941 | 0.84 | TDP1 (0.48) | TDP1CYP3A4TAAR1PARP1ALDH1A1 | |
| SCHEMBL27201211 | 0.78 | ALDH1A1 (0.66) | CYP3A4ACHETAAR1ALDH1A1IDO1 | |
| SCHEMBL6867025 | 0.78 | ALDH1A1 (0.54) | TDP1CYP3A4PARP1ALDH1A1CASP1 | |
| SCHEMBL3513675 | 0.77 | SKP2 (0.52) | TDP1CYP3A4TAAR1ALDH1A1 | |
| SCHEMBL20084779 | 0.76 | TAAR1 (0.40) | ACHETAAR1PTPN1IDO1MPO | |
| SCHEMBL20084450 | 0.75 | TAAR1 (0.42) | ACHETAAR1PTPN1ALDH1A1MPO | |
| SCHEMBL21970560 | 0.75 | SKP2 (0.50) | TDP1CYP3A4TAAR1ALDH1A1 | |
| SCHEMBL9610058 | 0.74 | SKP2 (0.53) | TDP1CYP3A4PARP1ALDH1A1CASP1 | |
| SCHEMBL21087071 | 0.74 | DAO (0.44) | TDP1ACHETAAR1PTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | TDP1 2021/4885CYP3A4 638/4885ACHE 599/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | TDP1 2021/4885CYP3A4 638/4885ACHE 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.